Danish biotech firm ZGene receives further investment boost  

Symbion Capital I and Danish Innovation Investment put DKK 15 million into the Danish biotech company ZGene

Symbion Capital I and Danish Innovation Investment (Dansk Innovationsinvestering) have put a capital injection of DKK 15 million (USD 2.2 million) into the Danish biotech company ZGene. The money will assist ZGene in reaching planned benchmarks over the next two years. ZGene has previously received capital from Danish Innovation Investment and NeuroSearch. The total amount raised by ZGene now amounts to DKK 22.2 million (USD 3.3 million).


ZGene owns the rights to a genetic activation system which dramatically increases the effect of existing anti-cancer drugs and accordingly reduces their toxic effects. ZGene has laboratories and offices at the Technical University of Denmark. The company was founded by private investors together with NsGene and Neurosearch. The news is reported by BiotechDenmark online.


Link > ZGene

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×